APHIG: a new multiparameter index for prostate cancer

Serum of 336 patients with primary prostate cancer (PC) with baseline total prostate-specific antigen level (totPSA) < 30.0 ng/ml was tested for free PSA (freePSA) and [-2]proPSA; %freePSA, %[-2]proPSA, prostate health index (phi), and a new index APHIG calculated using lab tests and taking into account age, T stage and Gleason score from biopsy were evaluated. Obtained data was compared to tumor stage (pTNM) and malignancy grade according to the Gleason score based on the final histological report after prostatectomy. APHIG has statistically significant benefits compared to PSA-associated markers for differentiation of clinically significant subgroups of PC: pT2c/pT3a/pT3b; local indolent PC/local aggressive/locally advanced/PC with regional metastases; total Gleason score 5–6/7(3 + 4)/7(4 + 3).

indolent and aggressive prostate cancer, prostate-specific antigen, totPSA, freePSA, [-2]proPSA, prostate health index

1. Catalona W.J., Partin A.W., Sanda M.G. et al. A multi-center study of [-2]Pro-prostate-specific antigen (PSA) in combination with PSA and free PSA for prostate cancer detection in the 2.0 to 10.0 ng/mL PSA Range. J Urol 2011;185(5): 1650–5.

2. Петрова Г.В., Каприн А.Д., Старинский В.В., Грецова О.П. Заболеваемость злокачественными новообразованиями населения России. Онкология. Журнал им. П.А. Герцена 2014;(5):5–10. [Petrova G.V., Kaprin A.D., Starinskiy V.V., Gretsova O.P. Morbidity of malignant neoplasms in Russian population. Onkologiya. Zhurnal im. P.A. Hertsena = Oncology P.A. Hertzen Journal 2014;(5): 5–10. (In Russ.)].

3. Sardana G., Dowell B., Diamandis E.P. Emerging biomarkers for the diagnosis and prognosis of prostate cancer. Clin Chem 2008;52(12):1951–60. DOI: 10.1373/clinchem.2008.110668. PMID: 18927246.

4. Postma R., Schröder F.H. Screening for prostate cancer. Eur J Cancer 2005;41(6):825–33. DOI: 10.1016/j.ejca.2004.12.029. PMID: 15808952.

5. Schröder F.H., Hugosson J., Roobol M.J. et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012;366(11): 981–90. DOI: 10.1056/NEJMoa1113135. PMID: 22417251.

6. Собин Л.Х., Господарович М.К., Виттекинд К. TNM. Классификация злокачественных опухолей. М.: Логосфера, 2011. [Sobin L.Kh., Gospodarovich M.K., Vittekind K. TNM. Classification of malignant tumors. Moscow: Logosfera, 2011. (In Russ.)].

7. Cantiello F., Russo G.I., Cicione A. et al. PHI and PCA3 improve the prognostic performance of PRIAS and Epstein criteria in predicting insignificant prostate cancer in men eligible for active surveillance. World J Urol 2015 [ahead of print].

8. Kryvenko O.N., Carter H.B., Trock B.J., Epstein J.I. Biopsy criteria for determining appropriateness for active surveillance in the modern era. Urology 2014;83(4):869–74. DOI: 10.1016/j.urology.2013.12.054. PMID: 24680457.

9. Han J.S., Toll A.D., Amin A. et al. Low prostate-specific antigen and no Gleason score upgrade despite more extensive cancer during active surveillance predicts insignificant prostate cancer at radical prostatectomy. Urology 2012;80(4): 883–8. DOI: 10.1016/j.urology.2012.05.045. PMID: 22921697.